An estimated 20 million people are diagnosed annually with cancer, while cancer kills almost 10 million people a year worldwide ( ) with these numbers expected to grow. The American Cancer Society ...

ABBV's growing oncology portfolio, now spanning five therapies, is helping offset Imbruvica's sales decline and boost ...

Merck said that a phase-three study of its pulmonary arterial hypertension treatment met its primary endpoints. On Monday, the pharmaceutical company said it has received positive topline results ...

Improving distant control of lung cancer is the most exciting potential benefit of combining JNJ-1900 with Keytruda (pembrolizumab), explained by Dr. Jared Weiss. JNJ-1900 is a novel radioenhancer ...

Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian cancer. The vaccine encodes PRAME, which the researchers found to be ...

“It is encouraging for CEL-SCI that Merck’s Keytruda application received the FDA’s priority review and that marketing approval was given based on a Phase 3 study’s first pre-specified interim ...

Merck & Co – known as MSD outside the US and Canada – has announced that its anti-PD-1 therapy Keytruda (pembrolizumab) has been approved by the US Food and Drug Administration (FDA) to treat a new ...

Keytruda is designed to enhance the immune system’s ability to detect and combat tumour cells. This humanised monoclonal antibody prevents PD-1 from interacting with its ligands, PD-L1 and PD-L2, ...

In May, Merck’s Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ovarian cancer whose tumors ...

Merck noted that it's estimated that in 2025, there will be approximately 72,680 new cases of head and neck cancer diagnosed, and more than 16,680 deaths from the disease.

Merck & Co.’s Keytruda has become the first immunotherapy approved by the FDA to be used around surgery to treat resectable locally advanced head and neck cancer. But the breakthrough approval ...